跳至主要内容
临床试验/CTRI/2019/01/017166
CTRI/2019/01/017166已完成未知

A blood test to determine the probability of developing cancer and/ or its stage, by analysing the expression profile of molecular immuno-markers in healthy and cancer patients (with histologically or cytologically proven malignancy-solid tumors or haematological malignancy) - BTDPC

Epigeneres Biotech Pvt Ltd0 个研究点目标入组 1,000 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Have any type of histologically or cytologically
  • proven (solid tumors or haematological ) cancer
  • which will assist in meeting the Primary
  • objective of this study (Cancer group)
  • ï?· Individuals who are NOT a known case of any
  • malignancy( Non-Cancer group)
  • ï?· Are aged 18 years or older.
  • ï?· Are willing to consent to storage of specimens for
  • future research.
  • ï?· Are willing to comply with study procedures and
  • follow-ups
  • ï?· Subjects enrolled will be able to provide
  • informed consent for themselves.

排除标准

  • Are incarcerated.
  • ï?· Are unwilling or unable to comply with
  • prescribed therapy.
  • ï?· Subjects that lack the capacity to provide
  • informed consent autonomously are to be
  • ï?· Pregnant or lactating women.
  • ï?· Subjects who have participated in any clinical
  • trial in the past 1 month.
  • ï?· Any subjects found to have entered into the study
  • in violation of this protocol or if the subject is
  • uncooperative during the study
  • ï?· Any other condition that in the opinion of the
  • investigator that does not justify the subjectâ??s
  • participation in the trial.

研究者

相似试验